SANTA CRUZ BIOTECHNOLOGY, INC.

UGT1A7 (B-12): sc-377075

SANTA CRUZ BIOTECHNOLOGY

The Power to Question

BACKGROUND

Glucuronidation, an important bile acid detoxification pathway, is catalyzed by enzymes belonging to the UDP-glucuronosyltransferase (UGT) superfamily. UGT genes are classified into the UGT1A and UGT2B subfamilies. Although each subfamily and each isoform shows tissue-specific patterns of distribution, the underlying mechanisms for this tissue specificity have not been fully elucidated. The human UDP-glucuronosyltransferase 1 (UGT1) locus encodes at least ten UGT1A proteins (UGT1A1-UGT1A10) that play a prominent role in drug and xenobiotic metabolism. Research indicates that nuclear receptors such as pregnane X receptor (PXR), constitutive androstane receptor (CAR) and peroxisome proliferator-activated receptor (PPAR) can regulate UGTs, which may contribute to the tissue-specific expression pattern of UGTs. Deficiency in the expression and/or activity of UGTs may lead to genetic and acquired diseases such as Crigler-Najjar syndrome and Gilbert syndrome. Based on their ability to catalyze the glucuronidation of xenobiotics and endobiotics, UGTs play a critical role in hormonal homeostasis, energy metabolism, bilirubin clearance and xenobiotic detoxification.

REFERENCES

1. Moghrabi, N., et al. 1992. Chromosomal assignment of human phenol and bilirubin UDP-glucuronosyltransferase genes (UGT1A-subfamily). Ann. Hum. Genet. 56: 81-91.
2. Owens, I.S., et al. 1996. The novel UGT1 gene complex links bilirubin, xenobiotics, and therapeutic drug metabolism by encoding UDP-glucuronosyltransferase isozymes with a common carboxyl terminus. J. Pharmacokinet. Biopharm. 24: 491-508.
3. Ciotti, M., et al. 1997. Genetic defects at the UGT1 locus associated with Crigler-Najjar type I disease, including a prenatal diagnosis. Am. J. Med. Genet. 68: 173-178.
4. Strassburg, C.P., et al. 1997. Differential down-regulation of the UDP-glucuronosyltransferase 1A locus is an early event in human liver and biliary cancer. Cancer Res. 57: 2979-2985.

CHROMOSOMAL LOCATION

Genetic locus: Ugt1a7 (mouse) mapping to 1 D.

SOURCE

UGT1A7 (B-12) is a mouse monoclonal antibody specific for an epitope mapping between amino acids 93-127 near the N-terminus of UGT1A7 of rat origin.

PRODUCT

Each vial contains 200 µg IgG_3 kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

Blocking peptide available for competition studies, sc-377075 P, (100 µg peptide in 0.5 ml PBS containing < 0.1% sodium azide and 0.2% stabilizer protein).

RESEARCH USE

For research use only, not for use in diagnostic procedures.

APPLICATIONS

UGT1A7 (B-12) is recommended for detection of UGT1A7 of mouse and rat origin by Western Blotting (starting dilution 1:100, dilution range 1:100-1:1000), immunoprecipitation [1-2 µg per 100-500 µg of total protein (1 ml of cell lysate)], immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500) and solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000).

Molecular Weight of UGT1A7: 55 kDa.

Positive Controls: rat liver extract: sc-2395 or rat kidney extract: sc-2394.

RECOMMENDED SUPPORT REAGENTS

To ensure optimal results, the following support reagents are recommended: 1) Western Blotting: use m-IgGκ BP-HRP: sc-516102 or m-IgGκ BP-HRP (Cruz Marker): sc-516102-CM (dilution range: 1:1000-1:10000), Cruz Marker™ Molecular Weight Standards: sc-2035, UltraCruz® Blocking Reagent: sc-516214 and Western Blotting Luminol Reagent: sc-2048. 2) Immunoprecipitation: use Protein A/G PLUS-Agarose: sc-2003 (0.5 ml agarose/2.0 ml). 3) Immunofluorescence: use m-IgGκ BP-FITC: sc-516140 or m-IgGκ BP-PE: sc-516141 (dilution range: 1:50-1:200) with UltraCruz® Mounting Medium: sc-24941 or UltraCruz® Hard-set Mounting Medium: sc-359850.

DATA



UGT1A7 (B-12): sc-377075. Western blot analysis of UGT1A7 expression in rat liver (**A**) and rat kidney (**B**) tissue extracts.

SELECT PRODUCT CITATIONS

1. Dong, S., et al. 2018. Upregulation of UDP-glucuronosyltransferases 1a1 and 1a7 are involved in altered puerarin pharmacokinetics in type II diabetic rats. Molecules 23: 1487.
2. Zhang, M.F., et al. 2019. Alteration of UDP-glucuronosyltransferase 1a1, 1a7 and P-glycoprotein expression in hepatic fibrosis rats and the impact on pharmacokinetics of puerarin. Phytomedicine 52: 264-271.

STORAGE

Store at 4° C, **DO NOT FREEZE**. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

CONJUGATES

See **UGT1A (B-4): sc-271268** for UGT1A antibody conjugates, including AC, HRP, FITC, PE, and Alexa Fluor® 488, 546, 594, 647, 680 and 790.